“Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP/TAZ) Lotion in Patients with Baseline Body Surface Area of 6 -12%” (2020) SKIN The Journal of Cutaneous Medicine, 4(5), p. s37. doi:10.25251/skin.4.supp.37.